Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HRR Deficiency”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07005583
What this trial is testing

Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple-Negative Breast Cancer (TNBC)
Tianjin Medical University Cancer Institute and Hospital 46
Testing effectiveness (Phase 2)Looking for participantsNCT03522064
What this trial is testing

Bipolar Androgen Therapy + Carboplatin in mCRPC

Who this might be right for
Castration-resistant Prostate CancerHomologous Recombination Deficiency
St Vincent's Hospital, Sydney 30
Testing effectiveness (Phase 2)Study completedNCT04508803
What this trial is testing

Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer

Who this might be right for
Treatment Efficacy
Fudan University 37
Not applicableUnknownNCT06242392
What this trial is testing

The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Fujian Cancer Hospital 250
Testing effectiveness (Phase 2)WithdrawnNCT03032614
What this trial is testing

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Who this might be right for
Breast Cancer Stage IVOvarian CancerBRCA1 Mutation+1 more
The University of Texas Health Science Center at San Antonio
Testing effectiveness (Phase 2)Ended earlyNCT04780945
What this trial is testing

Functional Analysis of BRCAness

Who this might be right for
Ovarian Neoplasm EpithelialHomologous Recombination DeficiencyBRCA1 Mutation+1 more
Leiden University Medical Center 27
Testing effectiveness (Phase 2)Study completedNCT05005728
What this trial is testing

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc. 72
Large-scale testing (Phase 3)Study completedNCT02855944
What this trial is testing

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Who this might be right for
Ovarian CancerEpithelial Ovarian CancerFallopian Tube Cancer+1 more
pharmaand GmbH 349
Testing effectiveness (Phase 2)Ended earlyNCT06964165
What this trial is testing

A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

Who this might be right for
Ovarian Neoplasms
Tesaro, Inc. 36
Large-scale testing (Phase 3)UnknownNCT03876886
What this trial is testing

The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency

Who this might be right for
Triple Negative Breast Cancer
Chinese Academy of Medical Sciences 200
Testing effectiveness (Phase 2)WithdrawnNCT03432676
What this trial is testing

Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer

Who this might be right for
ATM Gene MutationDeleterious BRCA1 Gene MutationDeleterious BRCA2 Gene Mutation+7 more
M.D. Anderson Cancer Center
Not applicableUnknownNCT04651933
What this trial is testing

A Training Set for the HRD Model in EOC

Who this might be right for
Epithelial Ovarian CancerBRCA MutationLoss of Heterozygosity+3 more
Lei Li 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT03742895
What this trial is testing

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

Who this might be right for
Advanced Solid Neoplasms
Merck Sharp & Dohme LLC 329
Testing effectiveness (Phase 2)Active Not RecruitingNCT05033756
What this trial is testing

Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO

Who this might be right for
Malignant Neoplasm of BreastBreast Cancer
Institut fuer Frauengesundheit 11
Testing effectiveness (Phase 2)WithdrawnNCT06120972
What this trial is testing

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

Who this might be right for
Ovarian Cancer
Alexander B Olawaiye, MD
Early research (Phase 1)Study completedNCT01017640
What this trial is testing

Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors

Who this might be right for
Solid Neoplasm
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)Ended earlyNCT03875313
What this trial is testing

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Who this might be right for
Solid TumorClear Cell Renal Cell CarcinomaTNBC - Triple-Negative Breast Cancer+4 more
Calithera Biosciences, Inc 33
Early research (Phase 1)Active Not RecruitingNCT06177171
What this trial is testing

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Who this might be right for
BRCA1 MutationBRCA2 MutationBRCA Mutation+3 more
Varun Monga, MBBS 13
Testing effectiveness (Phase 2)Study completedNCT04240106
What this trial is testing

Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)

Who this might be right for
Breast CancerBreast Cancer Metastatic
MedSIR 14
Early research (Phase 1)Active Not RecruitingNCT00777582
What this trial is testing

Phase I Comparative Bioavailability Study

Who this might be right for
Solid Tumors
AstraZeneca 197
Next Page